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Autoimmune diseases such as type 1 diabetes are complex in their pathogenesis. One approach to improving
our understanding of type 1 diabetes is the study of diseases that represent more extreme examples of auto-
immunity. Autoimmune polyendocrine syndromes (APS) are relatively rare diseases that often include type 1
diabetes as part of the disease phenotype. Recently, there has been tremendous progress in unraveling
some of the underlying mechanisms of APS. Here, we highlight the APS disorders with the perspective of
the clues they can offer to the pathogenesis and treatment of type 1 diabetes.Introduction
Extreme disease phenotypes, although often being rare, can
provide important insights into more common diseases. In the
case of type 1 diabetes (T1D), autoimmune polyendocrine syn-
dromes are such an example and have provided a wealth of
new information about disease pathogenesis. It has been long
noticed that patients with T1D have an increased risk for autoim-
munity targeting of other endocrine tissues such as the thyroid
and adrenal glands. In addition, there are collections of patients
that develop unique patterns of autoimmune endocrine pheno-
types that are segregated into different syndrome groupings.
Here, we describe these syndromes, our current understanding
of their pathogenesis, and how they relate to improving our
knowledge about the etiology of T1D.
Overview
Autoimmune polyendocrine syndromes (APS) are characterized
by functional insufficiency of multiple endocrine organs
secondary to an immunologically mediated destructive process
(Anderson, 2008). The name ‘‘polyendocrine’’ in these syn-
dromes is a bit of a misnomer because autoimmunity to nonen-
docrine organs is also seen in these disorders. Nonetheless,
many of the autoimmune processes in these disorders appear
to be associated with a progressive T cell-directed response
that results in organ damage and the production of organ-
specific autoantibodies similar to what is observed in isolated
T1D. A number of types of APS have been defined based on
genetic background and clinical features (Table 1) (Eisenbarth
and Gottlieb, 2004). At one end of the spectrum are the rare
monogenic polyendocrinopathies of APS type I (APS1) (OMIM
240300) (Perheentupa, 2006), as well as immunodeficiency,
polyendocrinopathy, and enteropathy, X-Linked Syndrome
(IPEX) (OMIM 304790) (Ochs et al., 2007). On the other end of
the spectrum, a much more common variation of the syndrome,
APS 2, is complex in its inheritance. All three of the autoimmune
polyglandular syndromes are characterized by a greatly
increased risk for the development of T1D (with IPEX > APS2 >
APS1), thus making APS a suitable avenue to pursue pathogenic
mechanisms of T1D. Table 1 summarizes some of the keydistinctions of the three separate groups of APS, which are
discussed below in further detail.
Autoimmune Polyendocrine Syndrome Type 1
Autoimmune polyendocrine syndrome type 1(APS1) is a child-
hood onset monogenic polyendocrine disease caused by muta-
tions in the autoimmune regulator AIRE (The Finnish-German
APECED Consortium 1997; Nagamine et al., 1997). The preva-
lence in Norway, which probably reflects the epidemiology in
many countries, is 1:90,000 (Bøe Wolff et al., 2008), but higher
frequencies are found in certain populations, including Finland
(1:25,000), Sardinia (1:14000), as well as among Iranian Jews
(Husebye et al., 2009). The other commonly used acronym for
this disease, APECED (autoimmune polyendocrinopathy-candi-
diasis-ectodermal dystrophy), illustrates the variety of clinical
manifestations. The main components of the syndrome are
chronic mucocutaneous candidiasis, hypoparathyroidism, and
primary adrenal insufficiency (Addison’s disease). The presence
of two of these components (one if a first-degree relative already
is diagnosed) is diagnostic (Ahonen et al., 1990). In addition,
a host of other manifestations in other endocrine glands (thyroid,
pancreatic islets, ovaries), the gastrointestinal tract, and ecto-
dermal structures are regularly seen (Table 1) (Ahonen et al.,
1990; Husebye et al., 2009; Perheentupa, 2006). A large pheno-
typic diversity is seen even among siblings, but on average, each
patient develops 4 components. Even if APS1 develops in early
childhood, late manifestations have been reported making the
distinction between APS1 and 2 difficult in some instances
where candidiasis and/or hypoparathyroidism are missing.
The identification and characterization of a number of autoan-
tibodies against tissue specific autoantigens has improved our
ability to diagnose APS1. Type 1 interferon autoantibodies
have proven to be particularly useful diagnostic tools to identify
these patients because virtually all APS1 patients reveal anti-
body reactivity to interferon alfa and/or interferon omega
subtypes (Meager et al., 2006; Wolff et al., 2007; Zhang et al.,
2007). Myasthenia gravis patients, especially those with late-
onset and thymoma, are the only other patient group with similar
autoantibodies (Meager et al., 2006). The clinical relevance ofImmunity 32, April 23, 2010 ª2010 Elsevier Inc. 479
Table 1. Characteristics of Autoimmune Polyendocrine Syndromes
Feature APS1 APS2 IPEX
Main components Addison’s disease Addison’s disease autoimmune enteropathy
hypoparathyroidism type 1 diabetes neonatal diabetes mellitus
mucocutanous candidiasis Autoimmune thyroid disease eczema
Frequency of diabetes 20% 50% >60%
Onset childhood adolescence, adulthood infancy
Gene and inheritance AIRE, autosomal recessive polygenic (MHC and others) FOXP3, X-linked
Female:male ratio equal female > male X-linked (male only)
Pathogenesis Autoreactive T cells escape
negative selection
unknown defect Treg leading to T cell
activation and proliferation
Immunologic phenotype high titer autoantibodies to
intracellular enzymes, interferons
and Th17 cytokines, candida
susceptibility
antibodies to affected organs;
anti-21OH (Addison’s disease),
GAD, IA-2 (type 1 diabetes)
lymphocytosis, eosinophilia,
overproduction of cytokines,
hyper IgE
Other common manifestations oophoritis, malabsorption,
hepatitis, asplenism, alopecia,
vitiligo, keratitis, enamel dysplasia
autoimmune gastritis, celiac
disease, vitiligo, oophoritis
autoimmune thyroid disease, eczema
haemolytic anemia, thrombocytopenia,
lymphadenopathy
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marker, remains to be determined because APS1 patients do
not demonstrate an increased susceptibility to viral infections.
In contrast, two recent studies have suggested that similar auto-
antibodies to the T helper 17 (Th17) cell cytokines IL-17A, IL-17F,
and IL-22 appear in APS1 subjects and may explain their
increased susceptibility to candidal infections (Kisand et al.,
2010; Puel et al., 2010). Although this data is strongly correlative,
further study will be needed to prove if defects in the Th17 cell
response are directly responsible for the candida susceptibility.
In addition to interferon and Th17cell-cytokine antibodies,
APS1 patients have high-titer autoantibodies to a number of
self-antigens, typically proteins with tissue-restricted expression
and often with a key function in their tissues (So¨derbergh et al.,
2004). Many are enzymes involved in neurotransmitter biosyn-
thesis or P450-containing enzymes involved in steroid synthesis
and metabolism. Autoantibody reactivity often correlates to
organ manifestations of the syndrome. For example, 21-hydrox-
ylase (a key enzyme in adrenal steroidogenesis) antibodies
correlate with adrenal insufficiency (So¨derbergh et al., 2004),
and tryptophan hydroxylase (involved in serotonin biosynthesis)
antibodies correlate with intestinal malabosorption (Ekwall et al.,
1999). Evidence that the hypoparathyroidism in the disorder is
secondary to an autoimmune response against the parathyroids
was bolstered by the recent identification of antibodies specific
for the parathyroid-specific protein NALP5 in APS1 patients with
hypoparathyroidism (Alimohammadi et al., 2008).
As mentioned above, APS1 subjects do show an increased
susceptibility to T1D; however, it does appear there are some
islet autoantibody differences in these subjects when compared
to isolated T1D subjects. For example, studies have shown that
APS1 subjects commonly develop anti-glutamate decarboxy-
lase 65 (GAD65), but there does not appear to be a correlation
of these antibodies to T1D (Gylling et al., 2000; So¨derbergh
et al., 2004). In contrast, both anti-insulin and anti-islet cell
antigen 2 (IA2) do correlate with T1D in these subjects (Gylling
et al., 2000; So¨derbergh et al., 2004). It is important to note
that GAD is an autoantigen that is not only expressed in the islets480 Immunity 32, April 23, 2010 ª2010 Elsevier Inc.but also in the nervous system andmay be part of the reason it is
not a good marker in APS1 for T1D.
Because APS1 is inherited in a monogenic autosomal reces-
sive fashion, human geneticists were able to identify the under-
lying defective gene through positional cloning efforts (The
Finnish-German APECED Consortium, 1997; Nagamine et al.,
1997) and termed it AIRE (for autoimmune regulator). Although
autoantibodies are highly indicative of the diagnosis, identifica-
tion ofmutations inAIRE is the ultimate proof of APS1, andmuta-
tions are found in over 95 percent of analyzed cases. More than
60 different mutations have now been reported, the majority of
which are translated into truncated and nonfunctional AIRE. It
remains controversial as to whether carriers of AIRE mutations
are predisposed to autoimmunity; however, experiments with
T cell receptor transgenic mice that are heterozygous carriers
of an Aire null mutation suggest that there could be a gene-
dosage effect in certain settings (Liston et al., 2004). One domi-
nant-negativemutation has been reported in an Italian family that
demonstrated an autosomal dominant inheritance pattern with
a high frequency of autoimmune thyroiditis (Cetani et al., 2001).
Importantly, a corresponding gene-targeted mouse model of
this mutation (G228W) in the SAND domain of Aire also develops
autoimmunity in a dominant fashion, but increased autoimmune
susceptibility was not seen in mice heterozygous for the Aire null
mutation in this study (Su et al., 2008).
APS1 is a challenge to treat and follow (Husebye et al., 2009;
Perheentupa, 2006). The number of manifestations and severity
of the disease varies greatly, and for many patients, the mor-
bidity and mortality is increased when compared to the general
population. The mainstay is replacement therapy for endocrino-
pathies, e.g., for adrenal insufficiency (cortisol and fludrocorti-
sones), diabetes mellitus (insulin), and hypoparathyroidism
(calcium and vitamin D). Autoimmune hepatitis, nephritis, and
exocrine pancreatic have responded to immunosuppressive
treatment, sometimes with regress of other APS1manifestations
such as alopecia and disappearance of circulating autoanti-
bodies (Ulinski et al., 2006; Ward et al., 1999). It is important to
note, however, that the use of immunosuppression in these
Immunity
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results. In addition, there is little published information on immu-
nosuppression and the reversal or improvement of T1D in APS1
subjects.
Immunodeficiency, Polyendocrinopathy,
and Enteropathy, X-Linked
Immunodeficiency, polyendocrinopathy, and enteropathy,
X-Linked syndrome (IPEX) is also an extremely rare but important
model disease characterized by a hyperactive T cells with both
autoimmune and allergic manifestations. Acronyms are X-linked
polyendocrinopathy, immune dysfunction, and diarrhea (XPID)
and X-linked autoimmunity and allergic dysregulation (XLAAD),
but IPEX is now the preferred name. Typically, IPEX manifests
itself in the perinatal period or in early infancy with chronic
diarrhea due to autoimmune enteropathy or diabetes mellitus.
Other common manifestations are eczematous dermatitis, auto-
immune thyroiditis (hypothyroidism predominates), autoimmune
cytopenias, and glomerulonephritis. The symptoms canwax and
wane; worsening can be precipitated by infections, vaccinations,
and dietary allergens. Eosinophilia and elevated serum amounts
of IgE and IgA are often reported in these patients, along with the
generation of autoantibodies tomany self-antigens. Although the
disorder has been linked to a defect in regulatory T cell function
(see below), there are reports that effector T cells in these
patients have defective IL-2 and gamma-interferon production
(Bacchetta et al., 2006). These patients also often display an
increased susceptibility to a wide number of severe infections
that include bacterial, viral, and fungal organisms (Powell et al.,
1982; Torgerson and Ochs, 2007).
T1D is commonly seen in this syndrome affecting more than
60% of reported subjects (Moraes-Vasconcelos et al., 2008)
and often manifests early with some infants already having
hyperglycemia at birth. Pancreatic tissue typically reveals
lymphocytic infiltration as seen in the more common form of
autoimmune diabetes (Moraes-Vasconcelos et al., 2008; Powell
et al., 1982; Wildin et al., 2002). Islet-specific antibodies are
present in many cases (islet cell antibodies, glutamic acid
decarboxylase antibodies), but this has not been studied exten-
sively because of the rarity of IPEX. Even growth hormone defi-
ciency and adrenal insufficiency have been described. Thus,
several of the manifestations in APS1 and IPEX overlap, but
overall, IPEX is a much more severe disease and many patients
die in infancy. Limited success has been observed with
long-term immunosuppressive therapy, and bone marrow
transplantation appears to be the treatment of choice for the
disorder in most cases (Mazzolari et al., 2005; Rao et al.,
2007; Zhan et al., 2008).
IPEX is caused by mutations in the FOXP3 gene located on
chromosome Xp11.3-q13.3. A wide number of mutations have
been described for patients with the disorder, and female
carriers have not been demonstrated to have an autoimmune
predisposition or related phenotype. However, there has been
a demonstration of the skewing of regulatory T cells to selectively
express the wild-type allele in these carriers (Di Nunzio et al.,
2009). There are patients that manifest milder manifestations of
the disorder, and there is a report of a specific point mutations
in FOXP3 being associated with this milder phenotype (De Ben-
edetti et al., 2006; Rubio-Cabezas et al., 2009).Autoimmune Polyendocrine Syndrome Type-2
Autoimmune polyendocrine syndrome type-2 (APS2) is much
more common than APS1 and usually commences later in life
than either APS1 or IPEX. APS2 is defined by the presence of
at least two of the following three diseases in the same patient:
T1D, Addison’s disease, and autoimmune thyroid disease.
Some investigators further subdivide this group of patients
(i.e., APS2, III, and IV), but patients with each of these subgroup
features can appear in the same family, and we, along with
others (Eisenbarth and Gottlieb, 2004), prefer to ‘‘lump’’ all of
these patients into the APS2 group. Females are more frequently
affected than males, and there is familial clustering of the
disorder. Again, like in APS1, affected family members will often
present with different autoimmune symptoms. In addition to the
major clinical features highlighted above, these patients will
often develop autoimmune gastritis, celiac disease, vitiligo,
and in female patients, oophoritis (Table 1) (Anderson, 2002;
Eisenbarth and Gottlieb, 2004; Kahaly, 2009). Unlike APS1
subjects, these patients do not develop hypoparathyroidism or
candidiasis.
Autoimmune Addison’s disease deserves a special note in
APS2 patients because it is more commonly associated
with the development of other autoimmune diseases than iso-
lated T1D or thyroiditis are. Addison’s is rare and has a prev-
alence of about 100 per million inhabitants and an incidence
is about 0.5 per 100 000 per year (Løva˚s and Husebye,
2002). Thyroiditis occurs in about 50% of patients with Addi-
son’s, while T1D occurs in about 15% of Addison’s patients
(Erichsen et al., 2009). In contrast, patients with thyroiditis
more commonly do not develop another autoimmune
problem, while patients with T1D have a moderate risk for
developing thyroiditis and Addison’s (Barker, 2006; Eisenbarth
and Gottlieb, 2004).
APS2 has a complex inheritance pattern with a strong linkage
to the HLA locus and association with a number of general auto-
immunity-associated genes (summarized in Table 2). Gene
discovery efforts in these patients has been somewhat
hampered by the relative rarity of APS2 and Addison’s subjects
when compared to isolated thyroidits or T1D. Thus, to date there
have not been sufficiently large collections of subjects to perform
adequately powered genome-wide association studies to iden-
tify risk genes for Addison’s disease and APS2. Despite these
limitations, there has been some progress in understanding
gene commonalities for T1D, thyroiditis, and Addison’s, which
is discussed further below.
Treatment of APS2 has generally been limited to replacement
hormone therapy. The disorder is generally not life threatening if
the disease components are recognized (particularly Addison’s)
and treated with proper hormone replacement. These subjects
rarely develop autoimmune features that require immunosup-
pression, such as autoimmune hepatitis or glomerulonephritis.
Thus, there is little treatment data in these patients as it relates
to immunomodulation or immunosuppression.
Molecular Mechanisms of APS:AIRE Function
and central tolerance
As outlined above the defective gene in APS1 is the Autoimmune
Regulator (AIRE). The AIRE protein is 545 amino acids long and
contains protein domains that suggest it plays a role inImmunity 32, April 23, 2010 ª2010 Elsevier Inc. 481
Table 2. Genes Associated with Addison’s Disease, Type 1 Diabetes, and Autoimmune Thyroid Disease
Addison’s disease Type 1 Diabetes Autoimmune Thyroid Disease
Gene class Gene or Variant Gene or Variant Gene or Variant
Organ-Specific Genes
? VNTR of the insulin promoter TSH Receptor (for Graves’ disease)
Immune-Related genes
MHC class I HLA-B HLA-C and HLA-B
MHC class II DR3-DQ2
DR4(DRB1*0404)-DQ8
DR3-DQ2
DR4(DRB1*0401 or DRB1*0404)-DQ8
DRB1
DQA1
Non-MHC CTLA-4 CTLA-4 CTLA-4
PTPN22 PTPN22 PTPN22
NALP1 NALP1
IL2Ra (CD25)
Immunity
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its expression to thymic medullary epithelial cells (mTECs) (An-
derson et al., 2002; Derbinski et al., 2001; Zuklys et al., 2000),
which we have come to appreciate as important regulators of
thymocyte tolerance (Derbinski et al., 2001). Within mTECs, it
appears that Aire helps promote tolerance by driving the tran-
scription of a wide variety of tissue-specific antigens (TSAs)
that are then displayed to the developing thymocyte repertoire
(Anderson et al., 2002, 2005; Liston et al., 2003). Thus, defects
in Aire result in a failure of central tolerance to a large number
of TSAs, and this is at least part of the explanation as to how
APS1 subjects develop autoimmunity in multiple target organs.
Importantly, it has been established that loss of thymic TSA
expression, even in the presence of Aire, is sufficient to predis-
pose to autoimmunity (DeVoss et al., 2006). Despite this
evidence, Aire may also regulate other properties in the thymus,
such as morphology, mTEC turnover, and cell trafficking, that
also influence tolerance (Gillard et al., 2007; Gray et al., 2007;
Yano et al., 2008).
T1D also has been logically connected to this tolerance
pathway (see Figure 1). First, it is clear that APS1 subjects
have an increased risk of developing T1D (Perheentupa, 2006)
and that Aire helps promote the expression of insulin within
mTECs (Anderson et al., 2002). Second, there has been a large
body of data connecting quantitative changes in thymic insulin
expression with diabetes genetic risk that maps to the variable
number of tandem repeat (VNTR) elements in the human insulin
promoter (Chentoufi and Polychronakos, 2002; Pugliese et al.,
1997; Vafiadis et al., 1997). Individuals with short VNTR elements
in the insulin promoter have an increased genetic risk of T1D and
lower amounts of thymic insulin expression. Recently, it has also
been demonstrated that these individuals harbor a higher
frequency of insulin-specific T cells by tetramer analysis when
compared to individuals with the protective insulin VNTR
element (Durinovic-Bello´ et al., 2010). Despite these logical
connections, there is still much that remains to be learned about
the tolerance pathway that Aire has helped reveal and its rela-
tionship to T1D. It is also interesting to note that variation in the
thyroid-specific gene product, the TSH-receptor, has been
linked to disease risk (TheWellcome Trust Case Control Consor-
tium, 2007; Dechairo et al., 2005), and it will be interesting to
determine if this risk also maps to thymic expression.482 Immunity 32, April 23, 2010 ª2010 Elsevier Inc.Molecular Mechanisms of APS:FOXP3 Function
and Regulatory T Cells
The defective gene in the IPEX syndrome was identified in 2001
through a complementary series of genetic studies involving
IPEX patients and a spontaneous mutant mouse line called
Scurfy (Bennett et al., 2001; Brunkow et al., 2001; Wildin et al.,
2001). In these studies, the forkhead-winged helix protein
Foxp3 was identified as the mutated gene in both mice and in
humans. Subsequent studies went on to demonstrate that
Foxp3 plays a critical role in the function of CD4+CD25+ regula-
tory T (Treg) cells (Fontenot et al., 2003; Hori et al., 2003; Khattri
et al., 2003). This work has opened up a large area of investiga-
tion on Treg cells beyond the scope of this review, including
studies on their development, stability, and functional activity
(Sakaguchi et al., 2008). Interestingly, there have also been
recent reports of patients with the clinical IPEX phenotype with
no evidence of mutations in FOXP3 (Caudy et al., 2007; Owen
et al., 2003; Zuber et al., 2007). One of these patients was found
to have mutations in CD25 (IL-2 Receptor alpha subunit) (Caudy
et al., 2007), which has been shown to play an important role in
the survival and stability of Treg cells (D’Cruz and Klein, 2005;
Fontenot et al., 2005). CD25 has also been known as a risk allele
identified in genome wide association studies on T1D (Maier
et al., 2009; Vella et al., 2005). Although expression amounts of
CD25 have correlated with genotype (Dendrou et al., 2009), it
remains open whether these risk alleles affect Treg cell function
or activity. Interestingly, a recent study also suggests that T1D
subjects may harbor other defects in functional IL-2 signaling
that has an effect of FOXP3 expression (Long et al., 2010).
Thus, CD25 defects in patients with T1D may be mapping to
a similar pathway as that which leads to T1D in subjects with
IPEX (Figure 1).
Functional Treg cell studies have also been pursued in
subjects with T1D. There appears to be no significant change
in the number or Treg cells in the peripheral blood of patients
with T1D (Brusko et al., 2005; Putnam et al., 2005); however,
several studies have demonstrated a defect in the in vitro
suppression assay used to measure Treg cell activity in patients
with T1D (Brusko et al., 2005; Lindley et al., 2005). Recently, it
has been suggested that the defect in this assay maps to the
resistance of T effector cells to suppression rather than a defect
in Treg cell function (Schneider et al., 2008). Taken together, the
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Figure 1. Autoimmune Polyendocrine
Syndrome Clues to Type 1 Diabetes
Pathogenesis
Shown is a schematic of central and peripheral
immune tolerancemechanisms that have been un-
raveled or suggested in the study of autoimmune
polyendocrine syndrome (APS) on the left and
correlates to potential tolerance mechanisms
found in type 1 diabetes (T1D) on the right. Work
on APS has been especially helpful in identifying
pathways (arrows) that control immune tolerance,
such as the activity of Aire in the thymus to drive
tissue-specific self-antigen expression and nega-
tive selection. APS-related defects in these path-
ways have been identified in both the central and
peripheral lymphoid organs (see text for further
details), and this has helped frame our under-
standing of tolerance mechanisms that have
been identified or suggested in the pathogenesis
of T1D (right).
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cells and their potential role in T1D pathogenesis (Figure 1).
APS2 Molecular Mechanisms
As outlined above, APS2 is not a single-gene disorder and has
a complex inheritance pattern. Certainly, one overarching reason
for multiple autoimmune phenotypes in these patients is related
to commonalities in genetic risk for the disease components. For
example, T1D, thyroiditis, and Addison’s disease all have had
disease risk mapped to the HLA, CTLA4, and PTPN22 genes
(Anderson, 2008). There are likely many other common genes
of APS2 that have yet to be robustly identified, again, due to
limitations in the numbers of patients that have been studied,
as discussed above. Similar to disease risk for isolated compo-
nents of APS2, the highest genetic risk maps to the HLA locus
with much lower risk conferred by non-HLA-linked genes such
as CLTA4 and PTPN22. Study of the HLA types in Addison’s
and T1D has demonstrated that many disease risk haplotypes
are shared between the disorders (Table 2). For example, the
DR3-DR4, DQ2-DQ8 haplotype is observed in over 30% of
Addison’s patients, which is also a risk haplotype for T1D (Yu
et al., 1999) (see Table 2). Further parsing of this haplotype has
determined that Addison’s patients commonly harbor the
DRB1*0404 subtype, which is also seen in T1D, but T1D subjects
that do not develop Addison’s often display the DRB1*0401
subtype. Part of this may be explained by recent work that has
suggested that the DRB1*404 allele can display epitopes of
adrenal 21-hydroxylase that DRB1*401 cannot (Bratland et al.,
2009).
Single nucleotide polymorphisms in the 30 untranslated region
of CTLA4 are associated with modest risk for thyroidits (odds
ratio 1:5) and slight risk for T1D (odds ratio 1:15). To further
explore the potential relationship of this gene to APS2, one
recent study examined a large cohort of T1D patients (>4,000)
and examined them for an association of thyroid autoantibodies
and the frequency of the CTLA4 risk polymorphism (Howson
et al., 2007). The authors found evidence for a stronger associa-
tion of the CTLA4 risk polymorphism in T1D patients that had
detectable thyroid autoantibodies than those that did not.
Interestingly, despite PTPN22 being reported as a risk gene forboth T1D and thyroiditis, there was no observable association
in this study. In contrast, another report had suggested that
the association of CTLA4 polymorphisms with T1D may be due
to the subset of the T1D patients that also were developing
thyroiditis (Ikegami et al., 2006). This was because no observable
risk was associated withCTLA4 in the subset of patients that had
T1D without thyroiditis. The differences in the studies may be
explained by the differences in patient populations and also
the clear data showing a weaker association of T1D with CTLA4.
A potential overlapping phenotype with APS2 are subsets of
patients that have vitiligo and autoimmunity. Many of these
patients develop thyroiditis, T1D, and Addison’s disease. Within
families that have this pattern, it appears that inheritance of
vitiligo is particularly strong when compared to the other autoim-
mune phenotypes. Because of this, there have been large-scale
efforts to map genetic risk in families that have vitiligo with other
autoimmune features, and recently, the NALP1 gene was re-
ported to have an association (Jin et al., 2007). NALP1 is likely
to play an important role in innate immune sensing, and there
is also evidence of association of this gene with Addison’s and
T1D (Magitta et al., 2009).
In addition to genetic approaches in APS2, there have been
functional studies onperipheral blood lymphocytes frompatients
with the disorder. One recent study found that APS2 subjects
harbored a defect in the suppressive function of CD4+CD25+
Treg cells, but not in their frequency ormarker expression pattern
(Kriegel et al., 2004). Unlike the study from the Buckner group on
T1D patients, this study mapped the defect directly to the Treg
cell population. Another group reported a defect in activation-
induced cell death and caspase-3 function in lymphocytes
from APS2 subjects, suggesting that a dysregulation of AICD
could be in play in the disorder (Vendrame et al., 2006). In both
cases, further studywill be needed to confirm these observations
and their molecular underpinnings but, again, may help
strengthen connections to T1D pathogenesis (Figure 1).
Future Opportunities and Conclusion
Despite the genetics of APS1 and IPEX being defined, there is
still much that can learned from these patients in regards to
T1D. For example, now that we understand that a major defectImmunity 32, April 23, 2010 ª2010 Elsevier Inc. 483
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patients could be a great resource for measuring autoreactive
T cells. With the advent of tetramer reagents to detect autoreac-
tive T cells in T1D (Durinovic-Bello´ et al., 2010), T cells fromAPS1
subjects with the proper MHC alleles could be valuable in the
development of tetramer assays given that they will likely harbor
a larger number of high-affinity T cells for self-antigens such as
insulin. The recent identification of a unique extrathymic Aire-ex-
pressing cell (eTAC) that appears to play a role in tolerance and
TSA expression (Gardner et al., 2008) also needs to be further
explored as it relates to T1D (Figure 1). Like Treg cells, these cells
may be more tractable for the induction of tolerance and
possible treatment of T1D because they appear to operate
through peripheral tolerance mechanisms. Early bone marrow
transplantation appears to be an effective treatment for IPEX
and reverses many of the autoimmune problems in the disorder.
However, in those subjects that have T1D, it appears that dia-
betes is irreversible. Perhaps optimization of the transplantation
protocol and the use of islet-specific Treg cells (Tang and Blue-
stone, 2006) as an adjunct could be explored in these subjects as
a means to improve T1D outcomes in these patients.
There are also a number of opportunities with APS subjects as
it relates to genetics. Although it is clear that a component of
APS2 pathogenesis is genetic, the identified shared risk genes
only appear to offer part of the explanation as to why multiple
autoimmune diseases are developing in these patients. The
modest effects of non-HLA genes such as PTPN22 and CTLA4
for disease risk in these subjects suggest that there may be as
yet other unidentified genes (i.e., ‘‘dark matter’’) at play in
APS2. One attractive area that should be explored in these
subjects is deep sequencing efforts to search for rare variants
(rather than common SNP variants) that may be in play in exert-
ing large effects that have not been appreciated (Altshuler et al.,
2008). In terms of AIRE and FOXP3, there have been efforts to
deep sequence both genes in large collections of subjects with
T1D with negative results (Nejentsev et al., 2009). Despite this,
there is precedent that unique mutations in AIRE and FOXP3
can give rise to distinct phenotypes from APS1 and IPEX,
respectively, and thus, unique mutations in these genes may still
contribute to T1D in settings that have not been tested to date.
Gene-gene interaction effects also should be further explored
in these disorders if possible, and there is evidence already for
this in APS1 for AIRE gene interactions with both the HLA (Halo-
nen et al., 2002) and the VNTR of the insulin gene (Adamson
et al., 2007) in relation to T1D risk.
Clearly, there has been substantial progress in our under-
standing of autoimmune polyendocrine syndromes and the
pathogenic mechanisms that underlie these disorders. As out-
lined in Figure 1, a picture is emerging where mechanistic
correlations between APS and T1D can now be made. Immune
tolerance is controlled by multiple pathways that operate at
many different layers of the immune system, and the study of
APS has helped reveal defects in both central and peripheral
tolerance pathways that contribute to autoimmunity. The frame-
work for these defects, highlighted in Figure 1, has proven to be
particularly useful in helping put together aworkingmodel of how
the significant but weaker gene influences identified in genome-
wide association studies of T1D are contributing to disease
pathogenesis. It is likely that in T1D, subtle defects in multiple484 Immunity 32, April 23, 2010 ª2010 Elsevier Inc.pathways are working in concert to drive disease pathogenesis,
and the severe defects that are present in APS have provided
a clearer picture of what the potential contribution of certain
pathways are to the autoimmune process. Moving forward, the
study of the immunology and genetics of APS will likely continue
to provide new insights into immune tolerance and will also
continue to help frame our understanding of T1D pathogenesis.ACKNOWLEDGMENTS
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